




Patent Docket P1093P1D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Manuel Baca et al. Serial No.: 09/723,752 Filed: November 27, 2000 For: ANTI-VEGF ANTIBODIES	Group Art Unit: To Be Assigned Examiner: To Be Assigned CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on June 26, 2001  Eileen Ly
---	---

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

Box Missing Parts
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This is responsive to the Notice to File Missing Parts - Filing Date Granted dated April 26, 2001.

Transmitted herewith are the following documents:

1. Certificate Re: Sequence Listing Response Under 37 CFR § 1.821(f) and (g).
2. Letter and Request to Use Computer-Readable Sequence Listing Under 37 CFR § 1.821(e).
3. Copy of Notice to File Missing Parts.
4. Preliminary Amendment.

Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

CLAIMS FOR FEE CALCULATION

Number Filed					
Number Extra		Rate			Basic Fee 37 CFR 1.16(a)
					\$710.00
Total Claims	17	- 20 =	0	X \$18.00	\$0.00

Independent	1	- 3 =	0	X \$80.00	\$0.00
Claims					
—	Multiple dependent claim(s), if any			+ \$270.00 ..	\$0.00
				
Filing Fee Calculation					\$710.00

Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$710.00.

The Commissioner is hereby authorized to deduct the appropriate surcharge fee of \$130 associated with this communication or credit any overpayment to Deposit Account No. 07-0630. A duplicate of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: June 26, 2001

By:

Steven X. Cui

Steven X. Cui

Reg. No. 44,637

Telephone No. (650) 225-8674



09157


PATENT TRADEMARK OFFICE



#5

Patent Docket P1093PID1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Manuel Baca et al. Serial No.: 09/723,752 Filed: November 27, 2000 For: ANTI-VEGF ANTIBODIES	Group Art Unit: Examiner: <div><p>CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p><p>June <u>24</u>, 2001</p><p> Eileen Ly</p></div>
---	--

CERTIFICATE RE: SEQUENCE LISTING

RESPONSE UNDER 37 CFR § 1.821(f) and (g)

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,

GENENTECH, INC.

Date: June 26, 2001

By: 

Steven X. Cui

Reg. No. 44,637

Telephone No. (650) 225-8674




09157

PATENT TRADEMARK OFFICE



Patent Docket P1093PID1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Manuel Baca et al. Serial No.: 09/723,752 Filed: November 27, 2000 For: ANTI-VEGF ANTIBODIES	Group Art Unit: Examiner: <div style="text-align: center;"><small>CERTIFICATE OF MAILING</small> <small>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</small> June 24, 2001  Eileen Ly</div>
---	---

Letter and REQUEST TO USE COMPUTER-READABLE SEQUENCE LISTING

UNDER 37 CFR §1.821(e)

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants respectfully request that the compliant computer-readable Sequence Listing filed in application Serial No. 08/908,469 be used as the computer-readable Sequence Listing for the present, above-identified application.

The paper copy of the Sequence Listing filed in the present application is identical to the computer-readable copy of the Sequence Listing filed in the application Serial No. 08/908,469.

Respectfully submitted,

GENENTECH, INC.

Date: June 26, 2001

By: 

Steven X. Cui

Reg. No. 44,637

Telephone No. (650) 225-8674



09157

PATENT TRADEMARK OFFICE

#91819



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/723,752	11/27/2000	Manuel Baca	P1093P1D1

CONFIRMATION NO. 6340

FORMALITIES LETTER



OC000000006011720

Attn: Steven X. Cui
GENENTECH, INC.
1 DNA Way
South San Francisco, CA 94080-4990

Date Mailed: 04/26/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 710 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 840.**
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

07/09/2001 EEKUBAY1 00000110 070630 09723752

01 FC:101 710.00 CH
02 FC:105 130.00 CH

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

A handwritten signature in black ink, appearing to read "Mam", is written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE